RxDoctor Payments Data

Matthew Block, MD

Medical Oncology · Rochester, MNNPI 1356359111

Payments from drug & device makers

What this record shows

This record is dominated by education: $11 of the $11 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Merck. That places this record below the midpoint for medical oncology clinicians in MN, where the typical reported total is $1,006.

$11in general payments, 2019–2025

Across 1 payment — averaging $10.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$11
$8,072,960in research payments, 2019–2025

Across 70 payments — averaging $115,328 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$4.4M
  • Genentech, Inc.$2M
  • E.r. Squibb & Sons, L.L.C.$777K
  • Pharmacyclics LLC, An Abbvie Company$767K
  • Alkermes, Inc.$97K
  • Regeneron$55K
  • plus $2K from 1 others

What the payments were for

  • Education$11100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck1$11

How this compares

$11 in reported general payments places this provider in the 5th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,822,706
Medicare patients
486
Services billed
89,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BraftoviEncorafenib38$459,418
MektoviBinimetinib39$421,053
LynparzaOlaparib27$344,713
Hydrocortisone11$492
Prednisone25$210
Prochlorperazine Maleate14$148
Levothyroxine Sodium14$89
Olanzapine15$80

Paid to pharmacies, not to this prescriber.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →